Singh T, Satheesh C T, Appaji L, Aruna Kumari B S, Padma M, Kumar M V, Mukherjee G
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore - 560 030, India.
Indian J Cancer. 2010 Jul-Sep;47(3):314-6. doi: 10.4103/0019-509X.64724.
The cornerstones of successful treatment of hepatoblastoma (HB) include preoperative chemotherapy followed by complete anatomical resection of tumor, followed by chemotherapy. Advances in chemotherapy in the last 2 decades have been associated with a higher rate of tumor response and possibly a greater potential for resectability.
We analyzed our single center experience with neoadjuvant chemotherapy (NACT) and surgery in HBs.
Our study included all children with HBs who received NACT and underwent surgical excision from January 1997 to July 2004.
Patient characteristics, clinical features, clinical course, treatment modalities, and long-term outcome were analyzed.
There were 9 boys and 3 girls, aged 5-60 months (median age at tumor diagnosis was 24 months). All received NACT containing cisplatin and doxorubicin. Of the 12 children, 9 underwent hepatectomy and among them, 4 patients each had right and left hepatectomy and 1 patient underwent right extended hepatectomy. After surgery, all patients completed rest of the chemotherapy course (total 6 cycles). R0 resection was carried out in all the 9 cases with no life-threatening complications.
Our experience of the 9 cases, although less in number, reaffirms the advantages of NACT followed by surgery. The prognosis for patients with resectable tumors is fairly good in combination with chemotherapy.
肝母细胞瘤（HB）成功治疗的基石包括术前化疗，随后进行肿瘤的完整解剖切除，然后再进行化疗。过去20年化疗的进展与更高的肿瘤反应率以及可能更大的可切除潜力相关。
我们分析了我们单中心在肝母细胞瘤新辅助化疗（NACT）和手术方面的经验。
我们的研究纳入了1997年1月至2004年7月期间所有接受NACT并接受手术切除的肝母细胞瘤患儿。
分析患者特征、临床特征、临床病程、治疗方式和长期结局。
有9名男孩和3名女孩，年龄5 - 60个月（肿瘤诊断时的中位年龄为24个月）。所有患者均接受了含顺铂和阿霉素 的NACT。12名儿童中，9例行肝切除术，其中4例分别行左右半肝切除术，1例行右半肝扩大切除术。术后，所有患者完成了其余的化疗疗程（共6个周期）。9例均实现R0切除，无危及生命的并发症。
我们9例的经验，尽管数量较少，但再次证实了NACT后手术的优势。可切除肿瘤患者联合化疗的预后相当好。
